



## Professor Colin Masters receives Australia Day Honours

**Sydney, 1 February 2017:** Actinogen Medical congratulates Professor Colin Masters on being appointed an Officer (AO) in the General Division of the Order of Australia for:

**“Distinguished service to medical research through international and national contributions to understanding Alzheimer’s and other neurodegenerative diseases”.**

Professor Masters is currently on Actinogen Medical, Xanamem™ Clinical Advisory Board and is the Executive Director of the Mental Health Research Institute, and a Laureate Professor at the University of Melbourne. He is also the Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital. He has focused his career on research in Alzheimer’s disease and other neurodegenerative diseases. With over 35 years’ experience, he is widely acknowledged as having had a major worldwide influence on Alzheimer’s disease research and the causes of the disease.

We are delighted for Professor Masters and his continued achievements in Alzheimer’s disease research.

**ENDS**

### Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen Medical's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer’s disease.

### About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer’s disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer’s disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. Xanamem™’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

**ACTINOGEN MEDICAL LIMITED** TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB [www.actinogen.com.au](http://www.actinogen.com.au)